Bijal D. Shah, MD
Advertisement
Articles by Bijal D. Shah, MD
Advertisement
Latest Updated Articles
Selecting the Appropriate BTKi in MCL and Potential Role of PirtobrutinibPublished: February 7th 2023 | Updated:
Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study HighlightsPublished: September 5th 2023 | Updated:
Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical TrialPublished: January 26th 2024 | Updated:
- Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?
Published: January 24th 2023 | Updated:
- Outcomes of the Retrospective, Multicenter ROCCA Analysis (Real-World Outcomes Collaborative of CAR-T in Adult ALL)
Published: February 9th 2024 | Updated:
- The Role of Bispecific Antibodies in Mantle Cell Lymphoma
Published: February 21st 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5